首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific
【2h】

Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific

机译:DNA错配修复蛋白hMSH6在卵巢癌中的丢失是组织特异性的

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Microsatellite instability (MSI) due to defects in DNA mismatch repair genes may be involved in the development of a subset of human ovarian carcinomas. The role of one such gene, hMSH6, in ovarian cancer is not well documented. We investigated the expression of hMSH6 protein in different histotypes of ovarian carcinoma and the associations between loss of hMSH6 protein and tumor grade, disease stage, familial history of cancer and patient survival. We stained an ovarian carcinoma tissue microarray consisting of formalin-fixed, paraffin-embedded tissue samples from 322 patients with an anti-hMSH6 antibody and scored the results semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein was noted in 20 of 230 serous carcinomas (8.7%), in 7 of 16 clear cell carcinomas (43.7%), in 4 of 34 endometrioid carcinomas (11.7%), in 1 of 14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated carcinomas. Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with clear cell, mucinous and endometrioid carcinoma histology (P<0.007). These findings indicate that loss of hMSH6 expression in ovarian carcinoma is more common in certain histologic subtypes, particularly in clear cell, endometrioid, and mucinous carcinoma, suggesting that loss of hMSH6 function may participate in the pathogenesis of these subtypes of cancer. Loss of hMSH6 expression did not predict survival and was not associated with disease stage, tumor grade, patient age or family history of cancer.
机译:由于DNA错配修复基因缺陷而引起的微卫星不稳定性(MSI)可能参与了人类卵巢癌的一个子集的发展。尚未充分证明一种这样的基因hMSH6在卵巢癌中的作用。我们调查了hMSH6蛋白在不同类型的卵巢癌中的表达以及hMSH6蛋白的缺失与肿瘤等级,疾病阶段,家族癌症史和患者生存率之间的关系。我们用抗hMSH6抗体对由322例福尔马林固定,石蜡包埋的组织样本组成的卵巢癌组织微阵列进行了染色,并对结果进行了半定量的阴性或阳性评分。由于染色过程中丢失了核心,因此排除了十二例病例。在230例浆液性癌中有20例(8.7%),16例透明细胞癌中的7例(43.7%),34例子宫内膜样癌中的4例(11.7%),14例恶性混合Müllerian肿瘤中的2例中均未发现hMSH6蛋白6例粘液癌,2例移行细胞癌中的0例和8例未分化癌中的0例。 hMSH6蛋白的丢失与存活率,患者年龄,肿瘤等级或疾病阶段无关,但与透明细胞,粘液性和子宫内膜样癌的组织学相关(P <0.007)。这些发现表明,在某些组织学亚型中,尤其是在透明细胞癌,子宫内膜样癌和粘液癌中,卵巢癌中hMSH6表达的丧失更为普遍,这表明hMSH6功能的丧失可能参与了这些亚型的发病机制。 hMSH6表达的丧失不能预测生存,并且与疾病阶段,肿瘤等级,患者年龄或癌症家族史无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号